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Summary
Context During a clinical trial of regular tetracosactide depot
injections, four of 13 patients with autoimmune Addison’s dis-
ease (AAD) developed adverse reactions immediately following
tetracosactide injections. We wished to investigate whether these
adverse effects could be due to the production of circulating an-
titetracosactide (ACTH1–24) antibodies.
Design Anti-ACTH binding activity was investigated using
immunoblotting and ELISA on sera from participants in the
trial (n = 13; baseline and after tetracosactide exposure), 131
unrelated patients with AAD, 92 patients with Graves’ disease
(GD), 15 patients with isolated ACTH deficiency and 102 con-
trols. Immunohistochemistry of human pituitary tissue sections
was also performed using pooled sera.
Results Bands at approximately 4 and 6 kDa, corresponding
to ACTH1–24 and full-length ACTH1–39, respectively, were
found in 10 of 13 (77%) of sera from trial patients exposed to
tetracosactide, including all those who had an adverse reaction.
This is in contrast with healthy control sera, which showed no
binding. The same 10 subjects also showed high levels of bind-
ing to tetracosactide by ELISA, along with 21% of patients with
AAD, 14% of patients with GD (both P < 0001 compared to
controls) and 1 isolated ACTH deficiency patient (7% of 15).
These sera also recognized native ACTH in human pituitary
sections.
Conclusion Our study demonstrates that repeated administra-
tion of depot tetracosactide can lead to anti-ACTH1–24 autoreac-
tivity. In addition, a significant number of patients with AAD
and GD also had similar, spontaneous, anti-ACTH reactivity.
The presence of these antibodies could mediate some of the
adverse effects or explain the well-described phenomenon of
resistance to chronic ACTH therapy.
(Received 18 January 2015; returned for revision 4 March 2015;
finally revised 27 March 2015; accepted 10 April 2015)
Introduction
The immune system is programmed to discriminate between
self- and non-self-peptides, with the aim of eliminating foreign
organisms and proteins that are harmful, but without generating
an immune response to endogenous self-peptides. Nevertheless,
tolerance to endogenous self-proteins can break down to pro-
duce autoimmune disorders, in which immune responses may
be directed against many different proteins, most typically
enzymes (e.g. thyroid peroxidase, steroid 21-hydroxylase, glutamic
acid decarboxylase) or cell-surface receptors (e.g. TSH receptor,
acetylcholine receptor and calcium-sensing receptor).1–5 In
addition, a lesser number of conditions are characterized by anti-
bodies against secreted peptide hormones, the most common of
which is type 1 diabetes in which anti-insulin antibodies are highly
prevalent.6,7
In a recent clinical trial, we administered high-dose synthetic
adrenocorticotrophic hormone (ACTH1–24 as zinc tetracosactide;
depot synacthen) to patients with autoimmune Addison’s disease
(AAD) in an attempt to stimulate adrenal regeneration (RoSA
study).8 However, towards the end of the study, four of 13
patients with AAD (all females) developed adverse reactions
immediately after tetracosactide injections during an ACTH1–24
stimulation test, despite having tolerated multiple depot tetraco-
sactide injections. One patient experienced generalized weakness,
heavy legs, nausea and abdominopelvic pain 5 min after tetraco-
sactide injection, which resolved after 70 min. Another patient
felt nauseous and lost consciousness for a few seconds, with
transient hypotension and abdominal cramps. Two other female
participants developed wheals at previous tetracosactide injection
sites, with itchiness and redness over their palms and soles. One
of the latter also experienced lower abdominal cramps and vom-
iting, followed by intermenstrual spot bleeding for 24 h. Fur-
thermore, one participant whose adrenal function initially
improved during ACTH1–24 therapy failed to sustain the clinical
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improvement. Despite the fact that ACTH is an endogenous
peptide to which immune tolerance should be established, these
phenomena made us wonder whether there were antibodies gen-
erated against the depot synacthen therapy.
ACTH is a polypeptide composed of 39 amino acids.9 The
amino N-terminal segment of the peptide (residues 1–24) is the
biologically active region of ACTH and is highly conserved
across vertebrate species, whereas the carboxyl terminal is con-
sidered to be more antigenic.10 Tetracosactide, also known as
cosyntropin or synacthen, is a synthetic polypeptide comprising
the amino-terminal 24 amino acids of ACTH. Depot tetracosac-
tide used in our clinical study has a prolonged duration of
action compared to soluble, unconjugated tetracosactide, as the
peptides are absorbed onto a zinc phosphate substrate, delaying
its absorption from the site of injection. In this study, we inves-
tigated the possibility that immunoreactivity towards tetracosac-
tide therapy developed in our trial patients, and we studied this
in additional patient cohorts.
Methods
Patients
Thirteen Caucasian patients with established AAD were
recruited for a clinical study entitled the revival of steroidogenic
function in AAD (RoSA; NCT01371526), either from the endo-
crine clinics of the Newcastle upon Tyne NHS hospitals
(n = 12), or from self-referred following an ethics committee
agreed advertisement in the national Addison’s disease self-help
group (ADSHG) quarterly newsletter (n = 1). Clinical details of
these patients and the trial have been provided elsewhere.8
The sera from 131 patients with AAD and 92 patients with
Graves’ disease were obtained via recruitment since 1996 through
outpatient endocrinology services in the North East of England
and the UK Addison’s disease self-help group. Sera from 102
patients with negative autoimmune screening (rheumatoid factor,
antinuclear antibody, antimitochondrial antibody, and anti-gas-
tric cell antibody) were obtained from the Clinical Pathology
department at Newcastle upon Tyne NHS hospitals trust. These
sera were used as ‘nonautoimmune’ controls. Fifteen Caucasian
patients with isolated ACTH deficiency were recruited either
from the John Hunter Children’s Hospital, Newcastle Australia
(n = 11) or from Newcastle upon Tyne NHS hospitals (n = 4).
This study was carried out with approval of the North East –
Sunderland Research Ethics Committee (ref. 12/NE/0101) and
the Hunter New England Human Research Ethics Committee.
Detection of antisynacthen antibodies by
immunoblotting
A 16% polyacrylamide tricine gel was run (90V, 1 h) with
25 lg of tetracosactide per well and was electroblotted
(350 mA, 45 min) onto Hybond C membrane (Amersham).
Patient and control sera were diluted 1:250 and incubated for
75 min at room temperature, following blocking with 5% nonfat
milk powder. Following washing, goat anti-human IgGc-chain-
horseradish peroxidase (HRP) (A6029; Sigma-Aldrich, Poole,
UK) was used to oxidize diaminobenzidine (DAB) substrate
(Sigma-Aldrich). Additional blots made using full-length human
ACTH1–39 (Sigma-Aldrich) were probed, and a monoclonal anti-
ACTH1–24 antibody (1B55; Santa Cruz, Dallas, CA, USA) was
used as a positive control (detected with goat antimouse IgG
(A4416, Sigma-Aldrich).
Detection of antitetracosactide antibodies by enzyme-
linked immunosorbent assay (ELISA)
Tetracosactide (ACTH1–24) was bound to the solid phase of
ELISA plates (NUNC maxisorp; Thermo Fisher Scientific,
Waltham, MA, USA) in a concentration of 1 lg/ml overnight at
4 °C in 19 carbonate coating buffer. Plates were washed three
times in phosphate-buffered saline Tween 20 (PBST; PBS, 1%
Tween 20) and blocked with 2% bovine serum albumin (BSA)
for 1 h at room temperature. Sera diluted to 1:250 in 2 mg/ml
BSA were incubated in plates at room temp for 75 min, fol-
lowed by washing and secondary antibody (goat anti-human
IgG c-chain-HRP) diluted 1:500 in 2 mg/ml BSA for 1 h at
room temperature. Following washing and detection with
3,30,5,50-tetramethylbenzidine (TMB) substrate (T0440; Sigma-
Aldrich) for 3 min, reactions were stopped by 1M hydrochloric
acid, and absorbance measured at A450 on an Ascent Multiskan
(Thermo Fisher Scientific). Antitetracosactide binding activity
was measured in triplicate for each participant sera, and each
result reproduced on at least two different days. Results are
expressed as arbitrary units of absorbance, having subtracted the
background absorbance (mean of three wells without serum).
The patient’s serum that showed the strongest antisynacthen
activity was selected as the positive control (serum of participant
6 at week 20, dilution at 1:250 in 2 mg/ml BSA). The positive
control was run on each occasion to check for interassay varia-
tion, which was within 10% on successive days. To check for
nonspecific serum binding to peptides, all positive samples were
run with an identical ELISA protocol, with plates coated with
octreotide (somatostatin 1–8) 1 lg/ml instead of tetracosactide.
Immunohistochemistry study of pituitary tissues
Human pituitary tissues fixed with 4% paraformaldehyde and
embedded in paraffin were sectioned in 4 lm sections. They
were immunostained using the indirect HRP-labelled antibody
method. Sections underwent deparaffinization and rehydration.
Antigens were retrieved by boiling the sections in Tris–EDTA
buffer (10 mM Tris Base, 1 mM EDTA solution, 005% Tween
20, pH 90) for 10 min in a microwave (850W). The sections
were allowed to cool for 20 min followed by two washes with
PBS plus 0025% Triton X-100. The sections were then blocked
with 10% goat serum in 1% BSA for an hour. This was followed
by 4 °C overnight incubation with pooled patient sera (from
three positive subjects) diluted 1:100. Following two washes with
PBS plus 0025% Triton X-100, sections were incubated in 1%
hydrogen peroxide for 15 min. The slides were then washed
twice prior to incubation with HRP conjugated goat anti-human
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Clinical Endocrinology (2015), 0, 1–7
2 E.H. Gan et al.
IgGc-chain antibodies (A6029; Sigma-Aldrich) for 1 h. Antibody
binding was visualized with the chromogen diaminobenzidine
(DAB) (Sigma-Aldrich) and counterstained with haematoxylin.
Monoclonal anti-ACTH1–24 antibody (1B55; Santa Cruz) was
used as a positive control (detected with goat antimouse IgG
(A4416; Sigma-Aldrich).
Results
Antitetracosactide immunoreactivity among patients in
the RoSA study
Sera from all of the patients who had an adverse reaction to
tetracosactide identified a approximately 4 kDa band on immu-
noblotting against the tetracosactide (ACTH1–24) peptide (Fig. 1
panel A). This band was found in 10 of 13 (77%) patients who
had received multiple doses of tetracosactide depot as part of
the clinical study. In most patients, the immunoreactivity devel-
oped over time during exposure to ACTH1–24, but in two of the
participants, there was reactivity at baseline before sustained
peptide exposure.
Immunoblotting against full-length ACTH1–39 peptide showed
that the patient sera which reacted with the tetracosactide pep-
tide also showed specific reactivity at approximately 6 kDa with
full-length ACTH peptide (Fig. 1 panel B). This is in contrast to
results from 3 healthy control sera, which showed no binding to
either the ACTH1–24 or the ACTH1–39 peptides. A commercial
anti-ACTH amino-terminal (corresponding to the tetracosactide
peptide) monoclonal antibody was used to probe blots and
showed bands corresponding to the expected size with both the
tetracosactide and the full-length ACTH peptides (Fig. 1 panel
B). An ELISA was then designed, using tetracosactide peptide
captured onto solid phase, to further quantify the antisynacthen
binding activity (see below for ascertainment of threshold of
normality). Sera from five of the 13 patients (38%; all female)
demonstrated relative absorbance above 021 units at baseline
(the threshold for positivity, see below) with 2 of them having a
relative absorbance of more than 2 units (Fig. 1 panel C). Upon
(A)
(B)
(C)
A B C D A B C D
Fig. 1 Antitetracosactide immunoreactivity detected
with immunoblotting and ELISA. Panel A:
Detection of serum binding activity to
immunoblotted ACTH1–24, at baseline and week
20 for participants 1, 6, 7 and 10, as assessed by
the band of approximately 4 kDa, the expected
molecular weight of ACTH1–24. Sera from healthy
subjects were used as a negative control. Panel B:
Immunoblotting was performed with blots made
using both tetracosactide (ACTH1–24) peptide and
full-length human ACTH1–39, both 25 lg per
well. Representative positive sera from two
participants (sera A and B), a monoclonal anti-
ACTH1–24 antibody (C) and serum from a healthy
control (serum D) are shown. The monoclonal
anti-ACTH antibody recognizes bands of the same
molecular mass as the positive participant sera for
both ACTH1–24 and ACTH1–39 peptides, which
was not seen with control sera. Panel C. Anti-
tetracosactide binding activity on immunoblotting
from all the patients of RoSA study was quantified
using ELISA. Results (SEM) are expressed as
arbitrary units of absorbance at 450 nM, having
subtracted the background absorbance (mean of
three wells without serum). A total of 11 females
and two males (04 and 08) participated in this
study. All except five patients had relative
absorbance units of less than 021 at baseline. A
positive control was run on each occasion to check
for interassay variation, which was within 10% on
successive plates.
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completion of either 10 or 20 weeks of tetracosactide therapy,
11 of 13 (846%) patients showed immunoreactivity towards
tetracosactide, with relative absorbance scores above 021 units.
Nine of the 13 participants (69%) demonstrated a 15- to 12-
fold increase in the ELISA absorbance score following tetracosac-
tide peptide treatment, but sera from both male patients were
negative throughout the study.
Antitetracosactide immunoreactivity among controls vs
patients with autoimmune diseases (autoimmune
Addison’s disease, Graves’ disease and isolated ACTH
deficiency)
The study of autoimmunity towards ACTH1–24 or ACTH1–39
peptide was extended to larger groups involving healthy con-
trols, patients with Graves’ disease, autoimmune Addison’s dis-
ease and isolated ACTH deficiency. Initially, 102 control sera
from anonymous hospital attendees with negative autoantibody
status were investigated, along with a patient serum that had
proven positive on immunoblotting. Only one of the 102 con-
trol sera exceeded 021 absorbance units in the ELISA (Fig. 2,
panel A). This value was then taken as an arbitrary threshold of
positivity. Of the sera from 131 patients with autoimmune Addi-
son’s disease, 28 (21%) were positive (>021 U) for antitetraco-
sactide binding on the ELISA assay. Similarly, sera from 92
patients with Graves’ disease and 15 with isolated ACTH defi-
ciency were run: 13 (14%) and 1 (7%) were positive, respec-
tively.
To investigate whether the antisynacthen peptide binding in
the ELISA could be attributable to nonspecific binding, all posi-
tive sera were tested in an identical assay, except that the plates
were coated with octreotide (somatostatin octapeptide) instead
of tetracosactide. None of the sera gave a positive signal in the
assay with octreotide (Fig. 2, panel B). Similarly, all positive
patient sera in the ELISA were tested against the tetracosactide
peptide on immunoblotting, and all 41 showed specific 4 kDa
binding (Fig. 2, panel C).
Immunohistochemistry study
Finally, we examined normal human pituitary sections by
immunohistochemistry to determine whether the patient sera
with antisynacthen binding activity would recognize native
ACTH in tissue sections. Figure 3 shows that these positive sera
produced cytoplasmic staining in a similar pattern to that of a
commercial anti-ACTH antibody.
Discussion
The development of serum anti-ACTH antibodies following
long-term porcine or synthetic full-length ACTH peptide thera-
pies was reported in the 1960s and 1970s.11,12 Glass and col-
leagues detected anti-ACTH antibodies using haemagglutination
and antigen displacement methods in 32% of 38 rheumatoid
arthritis subjects treated with long-term depot tetracosactide
(zinc tetracosactide).13 In line with these early observations, we
demonstrated the development of anti-tetracosactide and full-
length ACTH binding activities using immunoblotting among
77% of 13 patients with autoimmune Addison’s disease, treated
with 20 weeks of depot tetracosactide therapy. The concentra-
tion of these anti-ACTH antibodies also appeared to increase in
most, but not all subjects, with increasing time of exposure to
depot tetracosactide therapy.
Although antibodies to self-peptides should in theory not
occur, the development of antibodies to various peptide thera-
pies has been extensively reported. Anti-insulin antibodies were
observed in patients with diabetes treated with exogenous insu-
lin, leading to immunological resistance and poor glycaemic
control.14,15 A similar experience was found in patients treated
with growth hormone therapy and with enzyme replacement in
Gaucher’s disease.16–18 Hence, our finding is in keeping with this
phenomenon and may explain some of the side effects seen in
the RoSA study. In addition, modification of circulating tetraco-
sactide concentrations by sequestration or increased clearance
mediated by circulating anti-ACTH antibodies could account for
treatment failure in some of the patients and ‘treatment resis-
tance’ observed in one participant, who lacked a sustained
improvement during tetracosactide therapy. Indeed, Felber and
colleagues described inactivation of corticotropin following anti-
body formation towards porcine ACTH, using a radioimmuno-
assay.11 It has also been shown that antibodies generated in
guinea pigs immunized with synthetic full-length ACTH were
responsible for a loss of ACTH bioactivity in vitro.11 Further-
more, as antibodies against tetracosactide would be directed
against the biologically active amino acid sequence of ACTH,
the 1–24 segment, this clearly has the potential to reduce the
therapeutic potency and effectiveness of depot tetracosactide
therapy.
Intriguingly, the same autoreactivity has not been reported
with soluble synthetic tetracosactide. Indeed, animal studies
showed that whilst conjugates of the ACTH1–24 peptide were
antigenic, unconjugated ACTH1–24 peptide failed to induce an
antibody response in rabbits or guinea pigs.11,19 The N-terminal
segment (1–24) of ACTH peptide is highly conserved among all
species and is believed to have low antigenicity.10,12,20 Hence, it
seems likely that the complex of ACTH1–24 and zinc in the
depot tetracosactide formulation preparation may be important
in the generation of the humoral immune response.
Interestingly, five of the 13 participants from the RoSA study,
who were never previously exposed to depot tetracosactide,
demonstrated positive serum anti-ACTH binding activity at
baseline. Similar findings were noted in the larger cohort of
patients with Addison’s. These latter patients had all received
one or two soluble ACTH1–24 peptide injections during diagnos-
tic testing for Addison’s disease. Hence, we speculate that the
anti-ACTH antibody response could potentially have been gen-
erated from either previous exposure to soluble tetracosactide,
or more likely towards native, full-length endogenous corticotro-
pin. This group of patients may be more susceptible to the
breakdown of immune self-tolerance, by dint of their autoim-
mune Addison’s disease, but may also be susceptible owing to
the very high levels of endogenous plasma ACTH circulating in
© 2015 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
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the months before their diagnosis of AAD. Indeed, several previ-
ous studies have found an activity in the sera of patients with
AAD that appeared to attenuate the in vitro steroidogenic
response of cultured adrenal tissue to ACTH.21–23 Although this
was believed to be due to patient immunoglobulins that bound
to and blocked stimulation of the ACTH receptor, several of the
effects described would be consistent with antibodies that neu-
tralized ACTH action in vitro. This then begs the question, could
these ACTH antibodies that were found in 21% of the unrelated
patients with AAD in our cohort, contribute to the pathogenesis
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Fig. 2 Anti-tetracosactide binding activity detected
by ELISA and immunoblotting. Panel A. Relative
quantitation of anti-tetracosactide binding activity
using ELISA with sera from 102 controls, 131
unrelated patients with AAD, 92 patients with
Graves’ disease and 15 patients with isolated ACTH
deficiency. Tetracosactide (ACTH1–24) 1 lg/ml
was bound to solid phase ELISA plates (NUNC
maxisorp). Results (SEM) are expressed as
arbitrary units of absorbance at 450 nM, having
subtracted the background absorbance (mean of
three wells without serum). A positive control was
run on each occasion to check for interassay
variation, which was within 10% on successive
plates. ELISA of the 102 control sera (from
anonymous hospital attendees with negative
autoantibody status) showed absorbance readings
of ≤02 units in 101 sera, with 1 serum showing an
absorbance of 06 units. Panel B. All positive
samples were run against an identical ELISA
protocol, with plates coated with octreotide
(somatostatin 1–8) 1 lg/ml. None of the sera gave
a positive signal in the assay with octreotide. Panel
C. All positive patient sera in the ELISA were
tested against the tetracosactide peptide on
immunoblotting, and all 41 showed specific 4 kDa
binding. Representative positive sera from six
patients (A–F) are shown.
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of autoimmune Addison’s disease? If these antibodies had func-
tional consequences in terms of binding or clearing endoge-
nous ACTH, then a state of relative ‘corticotropin resistance’
could potentially lead to an accelerated decline in adrenal func-
tion during the natural history of evolving Addison’s disease.
Plasma ACTH may be elevated for many years prior to the
diagnosis of Addison’s disease24 and this ACTH drives small
islands of adrenal hyperplasia and regeneration,25,26 slowing the
ultimate onset of adrenal steroidogenic failure. Thus, early
adrenal unresponsiveness to ACTH stimulation in evolving
Addison’s disease may have the potential to tilt the balance
from subclinical or partial adrenal insufficiency to clinically
apparent adrenal insufficiency.
The significance of anti-ACTH antibodies in a small num-
ber of patients with Graves’ disease is also unknown, especially
in the absence of clinically apparent adrenal insufficiency.
Nevertheless, several studies have documented a blunted corti-
sol response to tetracosactide in hyperthyroid Graves’ disease,
which would be consistent with the effects of anti-ACTH anti-
bodies in these patients.27,28 It is also well known that patients
suffering from one autoimmune disease are susceptible to
development of a second autoimmune condition, manifesting
either as overt disease following pathological destruction of
self-tissue or as the presence of circulating autoantibodies
alone.
Following the demonstration that sera with anti-ACTH anti-
bodies recognized native ACTH in human pituitary sections
(Fig. 3), we also wondered whether anti-ACTH antibodies
could have a role in isolated ACTH deficiency, as previously
suggested in a single case report.29 On account of the rarity
of this condition, we were able to obtain sera from just a
small number of individuals, and only one serum sample
showed anti-ACTH binding activity. Whilst isolated ACTH
deficiency is a heterogeneous condition, a significant propor-
tion of individuals have coexisting autoimmune thyroid dis-
ease or manifest other features of autoimmunity, and the
target autoantigen has yet to be defined. Nevertheless, the
presence of anti-ACTH antibodies in just one (7%) of our
patient group suggests that although these antibodies would
be a logical mediator of isolated ACTH deficiency, they are
not a major cause of this condition. Larger cohorts of this
rare condition should be examined in the future to confirm
our preliminary findings.
In summary, this study demonstrates that repeated adminis-
tration of depot tetracosactide can lead to anti-ACTH autoreac-
tivity. In addition, a significant number of untreated patients
with AAD and GD also had similar autoreactivity (P < 0001 vs
controls). It is possible that these anti-ACTH antibodies medi-
ated some of the adverse effects seen in participants in the RoSA
study and that their generation in individuals following multiple
ACTH injections could explain the well-described phenomenon
of resistance to chronic ACTH therapy. In the future, further
investigation is necessary to more fully determine the role of
these anti-ACTH antibodies in the pathogenesis of autoimmune
Addison’s disease, isolated ACTH deficiency and other autoim-
mune conditions.
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Fig. 3 Cytoplasmic anti-ACTH1–24 staining of human anterior pituitary
sections. Immunohistochemistry was performed to identify whether sera
with anti-tetracosactide binding activity would recognize native ACTH
in contiguous tissue sections. Representative positive patient sera (panel
A) and negative patient sera (panel C) were used. Monoclonal anti-
ACTH1–24 antibody (1B55; Santa Cruz) was used as positive control
(panel B). The positive sera produced a cytoplasmic staining in a similar
pattern to that of the commercial anti-ACTH antibody.
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